DK1143958T3 - Farmaceutisk sammensætning med og anvendelse af R-NSAID til bekæmpelse af betændelser - Google Patents

Farmaceutisk sammensætning med og anvendelse af R-NSAID til bekæmpelse af betændelser

Info

Publication number
DK1143958T3
DK1143958T3 DK99968626T DK99968626T DK1143958T3 DK 1143958 T3 DK1143958 T3 DK 1143958T3 DK 99968626 T DK99968626 T DK 99968626T DK 99968626 T DK99968626 T DK 99968626T DK 1143958 T3 DK1143958 T3 DK 1143958T3
Authority
DK
Denmark
Prior art keywords
cox
nsaids
nsaid
action
mrna synthesis
Prior art date
Application number
DK99968626T
Other languages
English (en)
Inventor
William J Wechter
Original Assignee
Univ Loma Linda Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22517175&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1143958(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Loma Linda Med filed Critical Univ Loma Linda Med
Application granted granted Critical
Publication of DK1143958T3 publication Critical patent/DK1143958T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
DK99968626T 1998-09-03 1999-09-03 Farmaceutisk sammensætning med og anvendelse af R-NSAID til bekæmpelse af betændelser DK1143958T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14639598A 1998-09-03 1998-09-03
PCT/US1999/020261 WO2000013684A2 (en) 1998-09-03 1999-09-03 Pharmaceutical composition and method for treatment of inflammation

Publications (1)

Publication Number Publication Date
DK1143958T3 true DK1143958T3 (da) 2007-04-10

Family

ID=22517175

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99968626T DK1143958T3 (da) 1998-09-03 1999-09-03 Farmaceutisk sammensætning med og anvendelse af R-NSAID til bekæmpelse af betændelser

Country Status (13)

Country Link
US (1) US6472433B2 (da)
EP (1) EP1143958B8 (da)
JP (1) JP2002524415A (da)
CN (1) CN1391470A (da)
AT (1) ATE353010T1 (da)
AU (1) AU6026099A (da)
CA (1) CA2342628C (da)
CY (1) CY1106541T1 (da)
DE (1) DE69933049T2 (da)
DK (1) DK1143958T3 (da)
ES (1) ES2281981T3 (da)
PT (1) PT1143958E (da)
WO (1) WO2000013684A2 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
AU770803B2 (en) 1998-12-23 2004-03-04 Idea Ag Improved formulation for topical non-invasive application in vivo
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
DE10047319A1 (de) 2000-09-25 2002-04-18 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
KR20070086045A (ko) * 2004-11-12 2007-08-27 이데아 아게 피부 상태 치료에서의 확대된 표면 집합체
NZ564789A (en) * 2005-07-22 2010-07-30 Myriad Genetics Inc High drug load formulations and dosage forms
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP2468270A1 (en) 2010-12-21 2012-06-27 GALENpharma GmbH (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases
EP3078374B1 (en) 2011-10-17 2019-06-19 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
US20150183737A1 (en) * 2012-07-20 2015-07-02 Vanderbilt University Compositions and methods for substrate-selective inhibition of endocannabinoid oxygenation
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
CN113712960B (zh) * 2021-09-23 2023-04-07 南京医科大学 R-酮咯酸在防治主动脉夹层和主动脉瘤中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
DE4319438C1 (de) * 1993-06-11 1994-06-01 Gerd Dr Dr Geislinger Arzneimittel auf der Grundlage von Ketoprofen zur Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
IT1298214B1 (it) * 1998-01-28 1999-12-20 Dompe Spa Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche.

Also Published As

Publication number Publication date
CA2342628C (en) 2009-07-07
DE69933049D1 (de) 2006-10-12
WO2000013684A3 (en) 2002-05-30
JP2002524415A (ja) 2002-08-06
CN1391470A (zh) 2003-01-15
CA2342628A1 (en) 2000-03-16
DE69933049T2 (de) 2007-10-04
ES2281981T3 (es) 2007-10-01
US20010012849A1 (en) 2001-08-09
US6472433B2 (en) 2002-10-29
ATE353010T1 (de) 2007-02-15
CY1106541T1 (el) 2012-01-25
EP1143958B8 (en) 2007-05-23
EP1143958B1 (en) 2007-01-31
AU6026099A (en) 2000-03-27
PT1143958E (pt) 2007-04-30
EP1143958A3 (en) 2002-08-21
WO2000013684A2 (en) 2000-03-16
EP1143958A2 (en) 2001-10-17

Similar Documents

Publication Publication Date Title
DK1143958T3 (da) Farmaceutisk sammensætning med og anvendelse af R-NSAID til bekæmpelse af betændelser
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
UY24613A1 (es) Formula de liberacion controlada que comprende venlafaxina
ATE303162T1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
MX9308199A (es) Inhibidores de enzima.
BG104680A (en) Celecoxib compositions
DE60016402D1 (de) Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
IL166657A0 (en) Pharmaceutical compositions containing an agent effective to reduce the effective amount of clusterin
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
IL156827A0 (en) Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
AU4830097A (en) Use of an extract of Cimicifuga
DE50114474D1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
ATE290388T1 (de) Kombination von selen-haltigen verbindungen mit gemcitabin oder mitomycin c
GEP20043231B (en) Resorcinol Composition
DE60126591D1 (de) In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB
US20040023937A1 (en) Anti-cancer formulation
HK1049326B (zh) 具有治療和/或營養活性的活性成分的不吸濕的鹽以及含有它們的可口服的組合物
DK1399141T3 (da) Anvendelse af acetyl L-carnitin til fremstilling af et lægemiddel til forebyggende terapi af post-kirurgisk smerte
EA199700025A1 (ru) Применение олигосахарида и аспирина для приготовления медикаментов, предназначенных для лечения тромбоэмболических заболеваний, фармацевтическая композиция, способ лечения
PE20011042A1 (es) Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan
NO20005341D0 (no) Behandling av depresjon og farmasøytiske sammensetninger til dette
HUP0101428A2 (hu) Ciszteinproteázgátlót tartalmazó gyógyszerkészítmény agyszöveti károsodás megelőzésére és kezelésére